Alchemab Therapeutics today announced that it has initiated a Phase 1 first-in-human study of its antibody therapy ATLX-1282, licensed to Eli Lilly and Company in May 2025. According to the company, Lilly will lead later development and commercialization of ATLX-1282, while Alchemab conducts the initial clinical trial.
The company also revealed a $32 million extension to its Series A financing, bringing total Series A investment to $114 million. Investors in the extension include Ono Venture Investment, Lilly, and several existing specialist investors: RA Capital, SV Health Investors, DCVC Bio, and Lightstone Ventures.
Alchemab said the new funds will support advancement of ATLX-2847, its wholly-owned program targeting muscle atrophy via the prostaglandin pathway, into clinical development. The financing will also aid earlier programs in immune and neurological diseases and expand the company’s AI-enabled disease resilience-led discovery platform.
Alchemab’s platform, as described by the company, identifies protective auto-antibodies from “resilient” individuals, using machine learning and a large database (called DataCube) of over 6,000 patient-derived samples from more than 30 global collaborators.
The trials and funding extension follow prior collaborations with Lilly, including a January 2025 research collaboration to discover and commercialize up to five novel therapeutic candidates for neurodegenerative disease.
